Abstract: Disclosed herein are methods of increasing response to radiation therapy in subjects afflicted with cancer. In some embodiments, the method comprises reducing the ability of an immune suppressor cell (e.g., MDSC) to migrate to the microenvironment of the cancer. In some embodiments, the method further comprises suppressing the migration of the immune suppressor cell to a non-malignant cell and/or suppressing the malignant transformation of the non-malignant cells.

Abstract: Disclosed herein are methods of increasing response to radiation therapy in subjects afflicted with cancer. In some embodiments, the method comprises reducing the ability of an immune suppressor cell (e.g., MDSC) to migrate to the microenvironment of the cancer. In some embodiments, the method further comprises suppressing the migration of the immune suppressor cell to a non-malignant cell and/or suppressing the malignant transformation of the non-malignant cells.

Abstract: Disclosed herein are methods of increasing response to radiation therapy in subjects afflicted with cancer. In some embodiments, the method comprises reducing the ability of an immune suppressor cell (e.g., MDSC) to migrate to the microenvironment of the cancer. In some embodiments, the method further comprises suppressing the migration of the immune suppressor cell to a non-malignant cell and/or suppressing the malignant transformation of the non-malignant cells.

Abstract: The present invention provides a fusion proteins comprising (a) a first stretch of consecutive amino acids, the sequence of which is the sequence of an anti-p185her2/neu polypeptide or an anti-EGFR polypeptide; (b) a second stretch of consecutive amino acids, the sequence of which is the sequence of a polypeptide capable of binding at least one polypeptide other than p185her2/neu or EGFR; and (c) a third stretch of consecutive amino acids, the sequence of which comprises the sequence of a biologically active portion of interferon-gamma (IFN?), wherein (b) is located at the carboxy-terminal end of (a), and (c) is located at the carboxy-terminal end of (b). The present invention provides methods and compositions treating or preventing cancer and for sensitizing cancer cells to radiation or a chemotherapeutic agent, which comprises administering i) an anti-p185her2/neu antibody, an anti-EGFR antibody or an erbB kinase inhibitor and interferon-gamma (IFN?); or ii) a fusion protein of the invention.

Abstract: Disclosed is a spring steel wire rod that comprises C in a range of 0.35 to 0.65% (mass %, the same applies to respective elements described hereinafter), Si in a range of 1.4 to 2.2%, Mn in a range of 0.10 to 1.0%, Cr in a range of 0.1 to 2.0%, P not more than 0.025% (0% excluded), and S not more than 0.025% (0% excluded), balance comprising iron, and unavoidable impurities, wherein an average grain size Dc of a central part of the steel wire rod is not more than 80 ?m while an average grain size Ds of a surface layer part of the steel wire rod is not less than 3.0 ?m.

Abstract: Disclosed is a spring steel wire rod that comprises C in a range of 0.35 to 0.65% (mass %, the same applies to respective elements described hereinafter), Si in a range of 1.4 to 2.2%, Mn in a range of 0.10 to 1.0%, Cr in a range of 0.1 to 2.0%, P not more than 0.025% % excluded), and S not more than 0.025% (0% excluded), balance comprising iron, and unavoidable impurities, wherein an average grain size Dc of a central part of the steel wire rod is not more than 80 ?tm while an average grain size Ds of a surface layer part of the steel wire rod is not less than 3.0 ?m.